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General Considerations
Statistics can be used in a biological as-
say as either a method of checking on the
validity of conclusions or as a guide to the
interpretation of experimental results. The
division is sometimes made as one between
hypothesis testing and estimation. However,
the tool of hypothesis testing can be used
as an interpretive aid in conjunction with
the tools of estimation, so I prefer to make
the divisions in terms of the uses made by
the biologist.
If we are to apply statistical procedures
to the dominant-lethal trail as a check of
validity of conclusions, we would have to
consider the inherent theoretical faults in
the design. For instance, the animals actual-
ly treated constitute a small set of males and
any conclusions must be conditional upon
that set of males; thus, the probability levels
computed are, themselves, random vari-
ables, functions of the random choice of
males. Or, a typical trial will involve more
than one test compound or dose of a test
compound against the controls. Thus, any
formal probability level computed must take
into account questions of multiple compari-
sons. With comments like these, the statis-
tician can sit in the marble halls of his float-
ing island and throw bolts of doubt at the
whole procedure. But, almost any biological
assay can be made to suffer from this kind
of criticism. At this stage in the develop-
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ment of mutagenicity testing, statistics can
be much more effectively used to aid in the
organization and interpretation of empirical
results.
Three general problems face the experi-
menter in trying to organize and interpret
the results of a dominant-lethal trial. He
must be able to understand and display a
vast amount of data (typically, 10 males per
test group, 30 females per week, or 240 pair-
ed observations of implants and dead im-
plants per group). He must have a running
test procedure that will decide if a sub-
stance is to be suspected, a procedure with
known probabilities of false positive and
false negative results. He must be able to
estimate the degree of an effect if he suspects
one. A running test procedure will have to
make use of the formal terminology of hypo-
thesis testing. However, this is not a classical
situation. For instance, in view of the in-
herent vagaries of the animals, it may be
impossible to reduce the probability of false
positives to a fixed constant (such as 5%)
and the biologist may be forced to accept
what he can, relying on statistical techniques
to estimate the true running levels of error.
Review of the Literature
A detailed review of the literature from
a statistical point of view is given else-
where (1). Prior to 1970, statistics appear
to have been used strictly as a check on
validity. Chi-square contingency tables tend
to be presented to compare counts of im-
December 1973 51plants in order to "prove" the obvious by she chose to allow the analysis to run
computing significance levels of 1% or less. separately for counts of dead implants (esti-
Attempts to organize the results to derive mating postimplantation losses) and for
useful estimates of differential effect appear counts of total implants (estimating preim-
to be entirely without benefit of mathematical plantation losses).
clergy.
In 1970, KrUger (2) attempted to inter- Results of Investigations at Pfizer
pret the results of dominant lethal trials in At Pfizer, we were able to examine the
terms of a simple genetic mathematical data from over 4000 females taken during
model. He concluded that it was not possible --the control phases of more than 20 trials.
to estimate the mutagenic effect, uncon- From the analysis of this data we have de-
founded by other factors, and he proposed veloped an on-going method of computer
no useful tools of analysis. He did not have analysis which has enabled us to estimate
available raw data from these tests and could-- - the true alpha level of our procedure, and we
only check the validity of his model againt have been able to examine the value of our
mean counts in the published literature. prcedures with respect to known mutagens
On the other hand, Bishop (3) was able to and compounds of unknown mutagenic poten-
use a large number of control animals from tiaLnoDetails of our analysis of control data
actual experiments. She was able to estab- have been described elsewhere (1).
lish that the distribution of control data ;In general, we found that the number of
was sufficiently well behaved to allow for implants for a given pregnant female mouse
the use of standard robust statistical tech- - {all Charles River strain) can be effectively
niques. She set up a routine test method approximated by a binomial variate, as if
involving the use of a two-way analysis of there had been n implant sites, with each
variance with interaction [(weeks) x one having an independent opportunity to
(treatment)] and introduced the use of bear an implant with fixed probability p.
variance stabilizing transforms to deal with Thus, the number of implants y, found in
counts of dead implants. She has kindly sent the ith control female has a probability fre-
us a copy of her computer program. We have quency of the form
checked it against our data, and it appears
to be a very well-written and well-document- ( n) py(i-p)n-y
ed program that can effectively handle the Y
range of problems that might be expected The parameter p appears to be fixed at about
in running a dominant-lethal trial. 1/2, but the parameter n varies from one lot
The Bishop approach is much better than of females to another, ranging between 22
anything else appearing in the literature, and 26.
but it is still far from ideal. In particular, If the number of implants can be fitted to
it tests the overall mean levels of treat- a binomial (n;p), then the total number of
ments and makes no provision for testing implants in M pregnant females will also be
effects at specific stages of mutagenesis. In a binomial with parameters (Mn;p). Fur-
fact, a mild mutagen which affects the sperm thermore, if we let the occurrence of dead
during only one period will not produce a implants be a set of independent Bernoulli
statistically significant treatment effect (al- variables, conditional on the occurrence of
though it might produce a significant inter- an implant, with probability of death, r, then
action effect); and, thus, the method of Xi, the number of dead implants in the ith
testing chosen is ill-suited to the kind of al- female, has a conditional frequency of the
ternative hypothesis one might expect in form
real life. Bishop also failed to consider what
optimum combination of observations might X ( Yi ) r
work for a single mutagenic index. Instead, X
Environmental Health Perspectives 52From these theoretical considerations, it in April. There is also a significant (p<0.01)
can be shown that the total number of dead -upward trend in the number of dead im-
implants in M pregnant females has an un- plants.
conditional binomial distribution with para- -
meters (Mn;pvr) or a frequency of the - Methods-of-Analysis Now Being Used
form
( Mn) (pr)z (1-pr)M1"
If we assume that the effect of a mutagen
will be to change the parameters p (the
probability of an implant) or r (the condi-
tional probability of a death, given an im-
plant), then the number of implants and
dead implants will continue to have a bino-
mial distribution, even with a treatment
effect. Thus, the arcsine transformation will
stabilize the variance for both treatment and
controls, regardless of the effect of treat-
ment. This is not true of the square-root
transformation chosen by Bishop, since that
variance stabilization will hold only as
long as the probability of a dead implant
(r) remains small. By the arcsine transform,
we mean
Z = 2 [number of implants/nM, or 1/2
arcsine number of dead implants/nM f
Regardless of the underlying probabilities,
this transform has a variance 1/nWM. In our
running method of analysis, we chose n =
24. It is clear that the variances will remain
stabilized even if we have misestimated the
value of n, as long as the ratio under the
radical sign remains less than 1.0.
We have also examined the patterns of
change that occurred over time among our
control animals. There is a clear indication
that the control parameters change with
time. Figure 1 illustrates these changes. The
upper part of the figure displays the aver-
age number of implants per pregnant control
female (an estimate of n/2 in our binomial
model if we assume p is constant at 0.5)
across the entire 8 weeks of specific trials.
The lower part of the figure displays the
arcsine transform of the mean numbers of
dead implants. There is an apparent cyclic
pattern in the number of implants, with
peaks occurring in September and valleys
at Pfizer
We nowx have a running computer pro-
gram which is written in Fortran but is
mildly bound to the specific input/output con-
figurations of the PDP-10 computer. Copies
of the set of programs are available to any-
one who requests them, with the understand-
ing that some minor changes will have to be
made in the flow of data. The program pro-
duces four pages of output for each treat-
ment group. The first page lists the daily
counts of pregnant females, numbers of im-
plants, and rnumbers of dead implants that
form the basic input, along with appropri-
ate ratios and 3-day subtotals. This enables
the experimenter to see gross and obvious
patterns at a glance and to check for trans-
cription errors in the initial input data.
The second page displays mean levels of
implants, numbers of pregnant females, im-
plants, dead implants, living implants, and
ratios of these for each of the 8 weeks of
trial. This enables the investigator to see
the entire eight weeks of a single treatment
group together, to gain subjective or "gut
feeling" insights.
The third page is of the kind displayed
in Figure 2. This is a plot of mean daily
levels of a given measure (one of the z sta-
tistics described in the previous section or
one of the more sophisticated second-order
moment indices described in the next sec-
tion) against a regression plotted from the
mean daily control values. This regression,
based on controls is an important part of
the running analysis. In order to increase
the power of the test, the entire 8 weeks
of control values are compared against a
single week of treatment values. Early ex-
perience with the trial indicated that the
mean levels for controls tended to change
over the 8-week period, so it was inappro-
priate to compare the treatment values for
a single week against the overall mean of
the controls. Instead, we fit a linear regres-
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FIGURE 1. Control vs. experience over 2 years: (x) implants/pregnant female; (0) sin \/ p, where
p = dead implants/ pregnant females x 24.
sion against day of trial to the controls and
test a given week of treatment against that
regression. The computer plot displays 90%
and 95%o tolerance bands above the control
regression along with that estimated re-
gression. Thus, the investigator can see
graphically how and to what extent the
treatment values were beyond those pre-
dicted from control for a given week.
The final page of output displays the re-
sults of statistical tests comparing the mean
treatment levels for each week againt the
estimated control regression. In these tests,
we ignore the variance of the controls, and
we run a test which is conditional on the
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FIGURE 2. Control regression line and transformed EMS-360 data.
eight separate tests, one for each week. We
use a nominal 1 level to test each week.
The true alpha level is, of course, greater,
being a function of the control variance and
multiplicity of tests. Were all the tests in-
dependent and the control data without vari-
ance, the overall significance level would be
approximately 8%o. Our experience indicates
that we are running at about 9% false posi-
tives.
For theoretical purposes, we have com-
puted upper bounds on the control variance
and attempted to estimate the power of this
test (1). Estimates of the power are plotted
in Figure 3. The vertical axis represents the
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55Fig. 3 Probability of Detecting a Given
Change in Dead or Total Implants
per Pregnant Female
N = Number of pregnant females per group per day








% Increase 0 11.3 23.1 35%6 48.6-- -62.2 76.3 91.0 106.2 122.0
DEAD IMPLANT I I II I
Mean .77 .87 .95 1.04 1.14 125 1.36 1.47 1.59 1.71
% Decrease 0 2.0 4.0 6.0 8.0 - 10.0 12.0 14.0 15.9 17.9
TOTAL IMPLANTS I I I I I I
Mean 12.00 11.76 11.52 11.28 11.04 10.80 10.56 10.32 10.09 9.85
FIGURE 3. Probability of detecting -a given' change-n>deaad-or'total implants per pregnant female.
of the magnitude indicated on the hori- we can be 99% sure of detecting a doubling
zontal axis. Each ray represe*~ -a fixed-nui-u in the mean number of dead implants per
ber of females per group impregnated each female if we run at six pregnant females a
day. This figure suggests, for instance, that day.
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The actual daily observations from the
dominant lethal mutagenic trial consist of
a two-dimensional vector,
( number of implants
Vnumber of dead implants,J
It should be possible to derive from these
two numbers a single mutagenic index that
will cover both pre- and postimplantation
losses. In fact, a great deal of the pre-1970
literature deals with just this question. If
we fall back upon the binomial model pro-
posed above it can be shown that, if Xi =
number of dead implants for the ith female












The mean number of dead implants per preg-
nant female estimates E(X), and the mean
number of implants per pregnant female
estimates E(Y). It does not seem possible
to find ratios or simple linear combinations
of these two estimates that will be an in-
creasing function of both pre- and postim-
plantation losses. Table 1 displays various
indices based upon these two estimates,
with the appropriate combinations of para-
meters of which they are consistent estima-
tors. The columns labeled "conditions" show
that for some mutagenic conditions they will
tend to remain constant or actually decrease.
It would appear that any attempt to con-
struct a consistent estimator of a combina-
tion of parameters that will increase for
both pre- and postimplantation losses will
have to involve second order moments like
the variances or covariance. With clever
enough juggling of the formulae for expecta-
tion, variance, and covariance, a number
of such indices can be found. Two of these
indices are displayed in Table 1. If we use
the sample moments of the data, we can
construct moment estimators of such indices.
These are consistent estimators, but they
may be biased, and it might be possible to
find more efficient ones by means of maxi-
mum likelihood computations.
However, the present state of the art is
Table 1. Indices of mutagenic activity.,
Conditions
Index
Parameter r p r T but r
Verbal Symbolic estimated p 4 r T pr = k p t
Mean number of dead implants x npr 4 t
Number of dead implants/number of living implants 7/(V-i) pr/(1-pr) 4 1 1
Number of dead implants/number of implants TYV r -
Number of dead implants-number of living implants F-(V--) n(2pr-1) 1 1
(prob of death/number of implants) S'Y/(S,2V) r/np 1 1 1 4
(prob of death) X (unconditional prob of living) S28/1 * b r(1-pr) 1 t 1 4
Definitions:
p = Prob implant; r = Prob death, given an implant; n = number of implant sites; Xi = number of
dead implants, ith female; Yi = number of implants, ith female; m = number of pregnant females; r I =>






E(X) = npr Var(X) = npr(1-pr)
E(Y) = np Var(Y) = np(l-p)
Cov(X,Y) = npr(l-p) bD (SJ1297O5
December 1973 57such that we should first find a useful index
that can make sense to the biologist. So, in
our first tentative attempts to locate such an
index, we have restricted attention to these
moment estimators. It would appear, from
our first few runs, that the estimator, ln
(S'2/1) is the best of those tried, best in the
sense that it will declare statistical signifi-
cance for known mutagens and fails to call
significance for many of the situations we
have identified as false positives using mean
number of dead implants (or its arcsine
transform).
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